A Phase 2b clinical trial assessing the efficacy and safety of H.P. Acthar Gel, an experimental injectable therapy for amyotrophic lateral sclerosis (ALS), has enrolled half of its anticipated participants so far and is still open for recruitment. The trial, called PENNANT (NCT03068754), intends to enroll roughly…

Scientist Jingsong Zhou, PhD, has received a $2.88-million grant from the National Institutes of Health (NIH) to study how amyotrophic lateral sclerosis (ALS) affects multiple organs beyond the central nervous system (CNS). “We are ultimately working to find some potential therapeutic means to treat the disease with a…

Vitamin D supplementation can help overcome low levels of the vitamin often detected in people with amyotrophic lateral sclerosis (ALS). Still, such an alternative therapeutic approach has no meaningful clinical effect on progression of ALS-associated motor symptoms, a study suggests. The study, “…

High glucose levels might compensate for the toxic effects of an accumulation of TDP-43 — a widely expressed nuclear protein that binds both DNA and RNA — and protect neurons in amyotrophic lateral sclerosis (ALS), a study in a fly model of the disease suggests. The study,…

Researchers doing early-stage investigation into potential new ways to halt neuron death seen in amyotrophic lateral sclerosis (ALS) have received a grant from the Alabama Power Foundation. Rita Cowell, PhD, a researcher at Southern Research’s Drug Discovery division, and her team have identified certain compounds that in lab…

Scientist Manish Arora, PhD, received an $8 million Outstanding Investigator Award from the National Institute of Environmental Health Sciences (NIEHS) to develop models to predict and possibly prevent diseases such as amyotrophic lateral sclerosis (ALS). Arora and his team developed the Biodynamic Interface, which proposes an interplay…

Low levels of membralin protein in the brain cells that support and protect neurons lead to the accumulation of the neurotransmitter glutamate to levels that induce the death of motor neurons in amyotrophic lateral sclerosis (ALS), a mouse study shows. A gene therapy that rescued the levels of…

ALS and efficient are two words not often used in the same sentence. But to me, they are a perfect pairing. Mention “ALS” and it’s easy to think slow, clumsy, and low energy, while “efficient” can describe quick, streamlined, and well-organized. I’ve combined the two into what I call…

In the summer of 2014, the ALS Ice Bucket Challenge took social media by storm. Aimed primarily at raising awareness of the disease, the effort resulted in marked increases in spending on amyotrophic lateral sclerosis (ALS) research, an independent study shows. According to the report by…

MediciNova has launched the Phase 2b/3 clinical trial that will explore the potential of ibudilast (MN-166) in patients with amyotrophic lateral sclerosis (ALS). Pending the success of the trial, the collected data will support the submission of a new drug application and the approval of ibudilast…